BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 28968171)

  • 1. Randomized Phase III and Extension Studies of Naldemedine in Patients With Opioid-Induced Constipation and Cancer.
    Katakami N; Harada T; Murata T; Shinozaki K; Tsutsumi M; Yokota T; Arai M; Tada Y; Narabayashi M; Boku N
    J Clin Oncol; 2017 Dec; 35(34):3859-3866. PubMed ID: 28968171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Naldemedine versus placebo for opioid-induced constipation (COMPOSE-1 and COMPOSE-2): two multicentre, phase 3, double-blind, randomised, parallel-group trials.
    Hale M; Wild J; Reddy J; Yamada T; Arjona Ferreira JC
    Lancet Gastroenterol Hepatol; 2017 Aug; 2(8):555-564. PubMed ID: 28576452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients With Cancer.
    Katakami N; Oda K; Tauchi K; Nakata K; Shinozaki K; Yokota T; Suzuki Y; Narabayashi M; Boku N
    J Clin Oncol; 2017 Jun; 35(17):1921-1928. PubMed ID: 28445097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Phase 2b, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Chronic Noncancer Pain.
    Webster LR; Yamada T; Arjona Ferreira JC
    Pain Med; 2017 Dec; 18(12):2350-2360. PubMed ID: 28371937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized phase III and extension studies: efficacy and impacts on quality of life of naldemedine in subjects with opioid-induced constipation and cancer.
    Katakami N; Harada T; Murata T; Shinozaki K; Tsutsumi M; Yokota T; Arai M; Tada Y; Narabayashi M; Boku N
    Ann Oncol; 2018 Jun; 29(6):1461-1467. PubMed ID: 32151367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Onset of action of naldemedine in the treatment of opioid-induced constipation in patients with chronic noncancer pain: results from 2 randomized, placebo-controlled, phase 3 trials.
    Wild J; Yamada T; Arjona Ferreira JC; Hale M
    Pain; 2019 Oct; 160(10):2358-2364. PubMed ID: 31145214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and Efficacy of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Chronic Non-Cancer Pain Receiving Opioid Therapy: A Subgroup Analysis of Patients ≥ 65 Years of Age.
    Wild J; Webster L; Yamada T; Hale M
    Drugs Aging; 2020 Apr; 37(4):271-279. PubMed ID: 32086791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term use of naldemedine in the treatment of opioid-induced constipation in patients with chronic noncancer pain: a randomized, double-blind, placebo-controlled phase 3 study.
    Webster LR; Nalamachu S; Morlion B; Reddy J; Baba Y; Yamada T; Arjona Ferreira JC
    Pain; 2018 May; 159(5):987-994. PubMed ID: 29419653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of naldemedine for the treatment of opioid-induced constipation: A meta-analysis.
    Esmadi M; Ahmad D; Hewlett A
    J Gastrointestin Liver Dis; 2019 Mar; 28(1):41-46. PubMed ID: 30851171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Renal Impairment Subgroup Analysis of the Safety and Efficacy of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Chronic Non-Cancer Pain Receiving Opioid Therapy.
    Webster LR; Hale ME; Yamada T; Wild JE
    J Pain Res; 2020; 13():605-612. PubMed ID: 32280263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Naldemedine in Japanese patients with opioid-induced constipation and chronic noncancer pain: open-label Phase III studies.
    Saito Y; Yokota T; Arai M; Tada Y; Sumitani M
    J Pain Res; 2019; 12():127-138. PubMed ID: 30613161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A meta-analysis of naldemedine for the treatment of opioid-induced constipation.
    Song X; Wang D; Qu X; Dong N; Teng S
    Expert Rev Clin Pharmacol; 2019 Feb; 12(2):121-128. PubMed ID: 30652502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase 2, double-blind, randomized, placebo-controlled, dose-escalation study to evaluate the efficacy, safety, and tolerability of naloxegol in patients with opioid-induced constipation.
    Webster L; Dhar S; Eldon M; Masuoka L; Lappalainen J; Sostek M
    Pain; 2013 Sep; 154(9):1542-1550. PubMed ID: 23726675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Naldemedine is effective in the treatment of opioid-induced constipation in patients with chronic non-cancer pain who had a poor response to laxatives.
    Hale ME; Wild JE; Yamada T; Yokota T; Tack J; Andresen V; Drewes AM
    Therap Adv Gastroenterol; 2021; 14():17562848211032320. PubMed ID: 34377150
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Naldemedine: A Review in Opioid-Induced Constipation.
    Blair HA
    Drugs; 2019 Jul; 79(11):1241-1247. PubMed ID: 31267482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alvimopan, a peripherally acting mu-opioid receptor (PAM-OR) antagonist for the treatment of opioid-induced bowel dysfunction: results from a randomized, double-blind, placebo-controlled, dose-finding study in subjects taking opioids for chronic non-cancer pain.
    Webster L; Jansen JP; Peppin J; Lasko B; Irving G; Morlion B; Snidow J; Pierce A; Mortensen E; Kleoudis C; Carter E
    Pain; 2008 Jul; 137(2):428-440. PubMed ID: 18164818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized, Double-Blind Trial of Oral Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients with Chronic Noncancer Pain.
    Rauck R; Slatkin NE; Stambler N; Harper JR; Israel RJ
    Pain Pract; 2017 Jul; 17(6):820-828. PubMed ID: 27860208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Retrospective Study of the Efficacy and Safety of Naldemedine for Treatment of Opioid-Induced Constipation in Patients with Hepatobiliary Pancreatic Cancer.
    Kamiya T; Imai H; Fujita Y; Hiruta E; Masuno T; Yamazaki S; Tanaka H; Sandoh M; Takei S; Arai K; Nishiba H; Mogi J; Koizuka S; Saito T; Obayashi K; Kaira K; Minato K
    Medicina (Kaunas); 2023 Mar; 59(3):. PubMed ID: 36984494
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficacy and safety of naldemedine treatment for opioid-induced constipation in gastrointestinal cancer: a retrospective analysis.
    Nishiba H; Imai H; Fujita Y; Hiruta E; Masuno T; Yamazaki S; Tanaka H; Kamiya T; Ito M; Takei S; Matsuura M; Mogi J; Obayashi K; Minato K
    Ann Palliat Med; 2023 Jul; 12(4):697-707. PubMed ID: 37081703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Naldemedine for the treatment of opioid-induced constipation in adults with chronic noncancer pain.
    Liu JJ; Quinton SE; Brenner DM
    Pain Manag; 2020 Sep; 10(5):301-306. PubMed ID: 32552565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.